Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention

Emily K. Sims, Susan Geyer, Suzanne Bennett Johnson, Ingrid Libman, Laura M. Jacobsen, David Boulware, Lisa E. Rafkin, Della Matheson, Mark A. Atkinson, Henry Rodriguez, Maria Spall, Helena Elding Larsson, Diane K. Wherrett, Carla J. Greenbaum, Jeffrey Krischer, Linda A. DiMeglio

Research output: Contribution to journalArticle

Abstract

OBJECTIVE To better understand potential facilitators of individual engagement in type 1 diabetes natural history and prevention studies through analysis of enrollment data in the TrialNet Pathway to Prevention (PTP) study. RESEARCH DESIGN AND METHODS We used multivariable logistic regression models to examine continued engagement of eligible participants at two time points: 1) the return visit after screening to confirm an initial autoantibody-positive (Ab1) test result and 2) the initial oral glucose tolerance test (OGTT) for enrollment into the monitoring protocol. RESULTS Of 5,387 subjects who screened positive for a single autoantibody (Ab), 4,204 (78%) returned for confirmatory Ab testing. Younger age was associated with increased odds of returning for Ab confirmation (age <12 years vs. >18 years: odds ratio [OR] 2.12, P < 0.0001). Racial and ethnic minorities were less likely to return for confirmation, particularly nonwhite non-Hispanic (OR 0.50, P < 0.0001) and Hispanic (OR 0.69, P 5 0.0001) relative to non-Hispanic white subjects. Of 8,234 subjects, 5,442 (66%) were identified as eligible to be enrolled in PTP OGTT monitoring. Here, younger age and identification as multiple Ab1 were associated with increased odds of returning for OGTT monitoring (age <12 years vs. >18 years: OR 1.43, P < 0.0001; multiple Ab1: OR 1.36, P < 0.0001). Parents were less likely to enroll into monitoring than other relatives (OR 0.78, P 5 0.004). Site-specific factors, including site volume and U.S. site versus international site, were also associated with differences in rates of return for Ab1 confirmation and enrollment into monitoring. CONCLUSIONS These data confirm clear differences between successfully enrolled populations and those lost to follow-up, which can serve to identify strategies to increase ongoing participation.

Original languageEnglish (US)
Pages (from-to)2228-2236
Number of pages9
JournalDiabetes care
Volume42
Issue number12
DOIs
StatePublished - Dec 1 2019

Fingerprint

Type 1 Diabetes Mellitus
Autoantibodies
Odds Ratio
Logistic Models
Lost to Follow-Up
Glucose Tolerance Test
Natural History
Population

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Sims, E. K., Geyer, S., Johnson, S. B., Libman, I., Jacobsen, L. M., Boulware, D., ... DiMeglio, L. A. (2019). Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention. Diabetes care, 42(12), 2228-2236. https://doi.org/10.2337/dc19-0593

Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention. / Sims, Emily K.; Geyer, Susan; Johnson, Suzanne Bennett; Libman, Ingrid; Jacobsen, Laura M.; Boulware, David; Rafkin, Lisa E.; Matheson, Della; Atkinson, Mark A.; Rodriguez, Henry; Spall, Maria; Larsson, Helena Elding; Wherrett, Diane K.; Greenbaum, Carla J.; Krischer, Jeffrey; DiMeglio, Linda A.

In: Diabetes care, Vol. 42, No. 12, 01.12.2019, p. 2228-2236.

Research output: Contribution to journalArticle

Sims, EK, Geyer, S, Johnson, SB, Libman, I, Jacobsen, LM, Boulware, D, Rafkin, LE, Matheson, D, Atkinson, MA, Rodriguez, H, Spall, M, Larsson, HE, Wherrett, DK, Greenbaum, CJ, Krischer, J & DiMeglio, LA 2019, 'Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention', Diabetes care, vol. 42, no. 12, pp. 2228-2236. https://doi.org/10.2337/dc19-0593
Sims EK, Geyer S, Johnson SB, Libman I, Jacobsen LM, Boulware D et al. Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention. Diabetes care. 2019 Dec 1;42(12):2228-2236. https://doi.org/10.2337/dc19-0593
Sims, Emily K. ; Geyer, Susan ; Johnson, Suzanne Bennett ; Libman, Ingrid ; Jacobsen, Laura M. ; Boulware, David ; Rafkin, Lisa E. ; Matheson, Della ; Atkinson, Mark A. ; Rodriguez, Henry ; Spall, Maria ; Larsson, Helena Elding ; Wherrett, Diane K. ; Greenbaum, Carla J. ; Krischer, Jeffrey ; DiMeglio, Linda A. / Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention. In: Diabetes care. 2019 ; Vol. 42, No. 12. pp. 2228-2236.
@article{e1e54e3f55c640f082b8d65b19d49611,
title = "Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention",
abstract = "OBJECTIVE To better understand potential facilitators of individual engagement in type 1 diabetes natural history and prevention studies through analysis of enrollment data in the TrialNet Pathway to Prevention (PTP) study. RESEARCH DESIGN AND METHODS We used multivariable logistic regression models to examine continued engagement of eligible participants at two time points: 1) the return visit after screening to confirm an initial autoantibody-positive (Ab1) test result and 2) the initial oral glucose tolerance test (OGTT) for enrollment into the monitoring protocol. RESULTS Of 5,387 subjects who screened positive for a single autoantibody (Ab), 4,204 (78{\%}) returned for confirmatory Ab testing. Younger age was associated with increased odds of returning for Ab confirmation (age <12 years vs. >18 years: odds ratio [OR] 2.12, P < 0.0001). Racial and ethnic minorities were less likely to return for confirmation, particularly nonwhite non-Hispanic (OR 0.50, P < 0.0001) and Hispanic (OR 0.69, P 5 0.0001) relative to non-Hispanic white subjects. Of 8,234 subjects, 5,442 (66{\%}) were identified as eligible to be enrolled in PTP OGTT monitoring. Here, younger age and identification as multiple Ab1 were associated with increased odds of returning for OGTT monitoring (age <12 years vs. >18 years: OR 1.43, P < 0.0001; multiple Ab1: OR 1.36, P < 0.0001). Parents were less likely to enroll into monitoring than other relatives (OR 0.78, P 5 0.004). Site-specific factors, including site volume and U.S. site versus international site, were also associated with differences in rates of return for Ab1 confirmation and enrollment into monitoring. CONCLUSIONS These data confirm clear differences between successfully enrolled populations and those lost to follow-up, which can serve to identify strategies to increase ongoing participation.",
author = "Sims, {Emily K.} and Susan Geyer and Johnson, {Suzanne Bennett} and Ingrid Libman and Jacobsen, {Laura M.} and David Boulware and Rafkin, {Lisa E.} and Della Matheson and Atkinson, {Mark A.} and Henry Rodriguez and Maria Spall and Larsson, {Helena Elding} and Wherrett, {Diane K.} and Greenbaum, {Carla J.} and Jeffrey Krischer and DiMeglio, {Linda A.}",
year = "2019",
month = "12",
day = "1",
doi = "10.2337/dc19-0593",
language = "English (US)",
volume = "42",
pages = "2228--2236",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention

AU - Sims, Emily K.

AU - Geyer, Susan

AU - Johnson, Suzanne Bennett

AU - Libman, Ingrid

AU - Jacobsen, Laura M.

AU - Boulware, David

AU - Rafkin, Lisa E.

AU - Matheson, Della

AU - Atkinson, Mark A.

AU - Rodriguez, Henry

AU - Spall, Maria

AU - Larsson, Helena Elding

AU - Wherrett, Diane K.

AU - Greenbaum, Carla J.

AU - Krischer, Jeffrey

AU - DiMeglio, Linda A.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - OBJECTIVE To better understand potential facilitators of individual engagement in type 1 diabetes natural history and prevention studies through analysis of enrollment data in the TrialNet Pathway to Prevention (PTP) study. RESEARCH DESIGN AND METHODS We used multivariable logistic regression models to examine continued engagement of eligible participants at two time points: 1) the return visit after screening to confirm an initial autoantibody-positive (Ab1) test result and 2) the initial oral glucose tolerance test (OGTT) for enrollment into the monitoring protocol. RESULTS Of 5,387 subjects who screened positive for a single autoantibody (Ab), 4,204 (78%) returned for confirmatory Ab testing. Younger age was associated with increased odds of returning for Ab confirmation (age <12 years vs. >18 years: odds ratio [OR] 2.12, P < 0.0001). Racial and ethnic minorities were less likely to return for confirmation, particularly nonwhite non-Hispanic (OR 0.50, P < 0.0001) and Hispanic (OR 0.69, P 5 0.0001) relative to non-Hispanic white subjects. Of 8,234 subjects, 5,442 (66%) were identified as eligible to be enrolled in PTP OGTT monitoring. Here, younger age and identification as multiple Ab1 were associated with increased odds of returning for OGTT monitoring (age <12 years vs. >18 years: OR 1.43, P < 0.0001; multiple Ab1: OR 1.36, P < 0.0001). Parents were less likely to enroll into monitoring than other relatives (OR 0.78, P 5 0.004). Site-specific factors, including site volume and U.S. site versus international site, were also associated with differences in rates of return for Ab1 confirmation and enrollment into monitoring. CONCLUSIONS These data confirm clear differences between successfully enrolled populations and those lost to follow-up, which can serve to identify strategies to increase ongoing participation.

AB - OBJECTIVE To better understand potential facilitators of individual engagement in type 1 diabetes natural history and prevention studies through analysis of enrollment data in the TrialNet Pathway to Prevention (PTP) study. RESEARCH DESIGN AND METHODS We used multivariable logistic regression models to examine continued engagement of eligible participants at two time points: 1) the return visit after screening to confirm an initial autoantibody-positive (Ab1) test result and 2) the initial oral glucose tolerance test (OGTT) for enrollment into the monitoring protocol. RESULTS Of 5,387 subjects who screened positive for a single autoantibody (Ab), 4,204 (78%) returned for confirmatory Ab testing. Younger age was associated with increased odds of returning for Ab confirmation (age <12 years vs. >18 years: odds ratio [OR] 2.12, P < 0.0001). Racial and ethnic minorities were less likely to return for confirmation, particularly nonwhite non-Hispanic (OR 0.50, P < 0.0001) and Hispanic (OR 0.69, P 5 0.0001) relative to non-Hispanic white subjects. Of 8,234 subjects, 5,442 (66%) were identified as eligible to be enrolled in PTP OGTT monitoring. Here, younger age and identification as multiple Ab1 were associated with increased odds of returning for OGTT monitoring (age <12 years vs. >18 years: OR 1.43, P < 0.0001; multiple Ab1: OR 1.36, P < 0.0001). Parents were less likely to enroll into monitoring than other relatives (OR 0.78, P 5 0.004). Site-specific factors, including site volume and U.S. site versus international site, were also associated with differences in rates of return for Ab1 confirmation and enrollment into monitoring. CONCLUSIONS These data confirm clear differences between successfully enrolled populations and those lost to follow-up, which can serve to identify strategies to increase ongoing participation.

UR - http://www.scopus.com/inward/record.url?scp=85075813747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075813747&partnerID=8YFLogxK

U2 - 10.2337/dc19-0593

DO - 10.2337/dc19-0593

M3 - Article

C2 - 31558546

AN - SCOPUS:85075813747

VL - 42

SP - 2228

EP - 2236

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 12

ER -